Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also ...